Tamar Securities LLC Grows Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Tamar Securities LLC increased its holdings in Regeneron Pharmaceuticals by 37.9% in Q1, acquiring an additional 7,733 shares, bringing their total to 28,134 shares valued at approximately $17.84 million.
• Three analysts rated Regeneron Pharmaceuticals with a Strong Buy rating, while 18 analysts issued a Buy rating; the average target price for the stock is estimated at $817.67.
• Regeneron reported strong Q2 earnings with an EPS of $12.89, surpassing expectations, and announced a quarterly dividend of $0.88, yielding 0.6% annually.

Tamar Securities LLC raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 37.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 28,134 shares of the biopharmaceutical company's stock after buying an additional 7,733 shares during the quarter. Regeneron Pharmaceuticals makes up approximately 2.4% of Tamar Securities LLC's portfolio, making the stock its 21st biggest position. Tamar Securities LLC's holdings in Regeneron Pharmaceuticals were worth $17,844,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Pinney & Scofield Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. raised its stake in shares of Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 31 shares during the last quarter. Activest Wealth Management raised its stake in shares of Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 21 shares during the last quarter. Costello Asset Management INC purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $27,000. Finally, Saudi Central Bank purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $27,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock traded down $4.60 during trading hours on Friday, hitting $563.61. The stock had a trading volume of 237,972 shares, compared to its average volume of 1,094,638. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The stock has a market capitalization of $59.73 billion, a price-to-earnings ratio of 14.20, a PEG ratio of 1.86 and a beta of 0.35. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,170.58. The stock's fifty day moving average is $564.31 and its two-hundred day moving average is $580.78.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.43 by $4.46. The company had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.Regeneron Pharmaceuticals's revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $11.56 earnings per share. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Jefferies Financial Group increased their price objective on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a "buy" rating in a research report on Wednesday, August 27th. UBS Group reiterated a "neutral" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Guggenheim increased their price objective on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Sanford C. Bernstein increased their price objective on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 27th. Finally, Citigroup reiterated a "buy" rating and issued a $650.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Three research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $817.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.